All In Biotech

Drug Trial Radar · NCT01893190

Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage

Last checked: Nov 19, 2026Latest source record: Feb 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Sep 2013

Primary completion

Jan 2016

Study completion Jan 2016

Sponsor

Lead sponsor
Edge Therapeutics IncIndustry
Sponsor type
Industry
First posted
Jul 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2a Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study Comparing EG-1962 and Nimodipine in Patients with Aneurysmal Subarachnoid Hemorrhage

Conditions

  • Ruptured Cerebral Aneurysm
  • Ruptured Berry Aneurysm

Interventions

  • NimodipineDrug

    Based upon Investigator Judgement

  • Nimodipine MicroparticlesDrug

    Based upon Investigator Judgement

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation PeriodTime frame: 3 Months

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Rush University Medical Center

    Chicago, Illinois

  • University of Maryland Medical Cnter

    Baltimore, Maryland

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Overlook Medical Center

    Summit, New Jersey

  • University of New Mexico

    Albuquerque, New Mexico

  • Mount Sinai Medical Center

    New York, New York

  • Columbia University

    New York, New York

  • Lenox Hill Hospital

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Mayfield Clinic Inc

    Cincinnati, Ohio

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina

  • Vanderbilt University

    Nashville, Tennessee

  • University of Calgary, Foothills Medical Centre

    Calgary, Alberta, Canada

  • University of Alberta Hospital

    Edmonton, Alberta, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • University Health Network - Toronto General Division, Toronto Western Hospital

    Toronto, Ontario, Canada

  • University of Saskatchewan, Royal University Hospital

    Saskatoon, Saskatchewan, Canada

  • Charles University, Department of Neurosurgery

    Prague, Czechia

  • Helsinki University Central Hospital

    Helsinki, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.